سعر ريزوديج 100 وحدة دولية/مل فليكسوتاتش اقلام معبأة للحقن 2024

• Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.Population: Adults, adolescents and children >=2 yearsEuropean Medicines Agency (EMA)

• Most frequently reported adverse reaction is hypoglycaemia.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to the active substances or to any of the excipients.International label, same formulation · European Medicines Agency (EMA)

• Hypoglycaemia may occur with missed meals or unplanned strenuous exercise; hyperglycaemia with inadequate dosing; transfer between insulins requires close glucose monitoring.International label, same formulation · European Medicines Agency (EMA)
• Cardiac failure has been reported with pioglitazone plus insulin, especially in patients with risk factors; monitor and discontinue pioglitazone if cardiac symptoms worsen.International label, same formulation · European Medicines Agency (EMA)

• PioglitazoneCases of cardiac failure reported with pioglitazone combined with insulin; observe for heart failure signs.European Medicines Agency (EMA)
• MAOIs, beta-blockers, ACE inhibitors, salicylates, anabolic steroids, sulfonamides, oral antidiabetics, GLP-1 agonistsMay reduce insulin requirement (hypoglycaemia risk); beta-blockers may mask hypoglycaemia symptoms.European Medicines Agency (EMA)

• No clinical experience in pregnant women; animal studies showed no difference from human insulin regarding embryotoxicity/teratogenicity. Intensified glucose control and monitoring recommended throughout pregnancy.International label, same formulation · European Medicines Agency (EMA)
• No clinical experience during breastfeeding; unknown whether excreted in human milk; no metabolic effects anticipated in the breastfed infant.International label, same formulation · European Medicines Agency (EMA)

English text not available for this section.